Clinical Impact of Busulfan Pharmacokinetic Monitoring in Pediatric Allogeneic Transplants: Perspectives from A Transplant Center in A Low- and Middle- Income Country.
AI interpretation is pending for this paper.
Open original publication →What the AI sees
Not AI summarized yet.
Research significance
Pending deeper interpretation.
Source abstract
We evaluated the impact of busulfan pharmacokinetic (Bu‑PK) monitoring on toxicity and outcomes in pediatric patients undergoing busulfan-based myeloablative HSCT for benign (n = 221) and malignant diseases (n = 15) at our center in India (January 2023-December 2025). Bu‑PK using liquid chromatography-tandem mass spectrometry was available to 93 patients whose toxicity and outcomes were compared to 143 patients in whom Bu-PK was not done. Once-daily intravenous busulfan was administered over 3 h. Median busulfan dose administered was 105.3 (IQR 93.2-127.6)% with a wide range of 41.7%-213.1% of the standard weight-based dosing, with no added toxicity in those receiving doses >125% of the weight-based dose. Infections, particularly CMV reactivation, were more frequent in the Bu‑PK group with no increase in mortality. Mixed chimerism was significantly lower in the Bu‑PK group (4.6% vs. 24.1%), with an 84% reduction in odds (OR = 0.16, 95% CI 0.05-0.43, p < 0.001). The implementation of monitoring was crucial for overcoming pharmacokinetic variability, reducing mixed chimerism, while maintaining an acceptable overall toxicity profile in our pediatric cohort.